Particle Sciences to open new commercial facility
New facility will offer customers the full range of services from development through to commercial-scale manufacturing
Particle Sciences, a Lubrizol LifeSciences company and US-based pharmaceutical CDMO, is opening a new commercial drug product manufacturing facility at the end of Q4 2018.
Located on its existing site in Bethlehem, PA, it is as part of an overall business unit investment of $60 million.
The 5,000 sq. ft facility will leverage Particle Sciences’s knowledge in complex formulations and drug product manufacturing, enabling the CDMO to offer customers the full range of services from development through to commercial-scale manufacturing.
Located next to the existing development and clinical trial manufacturing site, it will accommodate both sterile and non-sterile finished drug products, such as ophthalmics, drug-device combination products, injectables, micro- and nanoparticulate formulations and lyophilized drugs.
The new space was purpose-built for more complex drug products and features state-of-the-art utilities to accommodate the production of Water for Injection (WFI) and clean steam for clean-in-place processes.
Dr Robert Lee, newly-appointed president at Particle Sciences, said “Our new facility will extend our manufacturing capabilities to phase III clinical trial materials and commercial product manufacturing.
“Present and future clients will benefit from the wide variety of dosage forms that the facility can handle as well as our ability to accommodate the smaller commercial batch volumes that other CMOs will not take on.”
The new facility forms part of a wider investment by Lubrizol LifeSciences to strengthen its key capabilities, focusing on new product solutions, capacity expansion and additional commercial manufacturing.
It is expected to increase employment at Particle Sciences by 30% with jobs ranging from production and quality control positions to support functions such as analytical services.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance